Jinxin Shuanghe

Beijing Jinxin Shuanghe Pharmaceutical is a key manufacturing and development subsidiary of China Resources Double-Crane Pharmaceutical (CR Double-Crane). The company is primarily recognized for its robust portfolio in the cardiovascular and endocrine therapeutic areas, with a specific emphasis on oral solid dosage forms. Its leading products include widely prescribed treatments for type 2 diabetes and hypertension, such as Gliclazide and various compound antihypertensive formulations. Operating out of Beijing, the company maintains high-standard GMP production lines to supply the domestic Chinese healthcare system with essential chronic disease medications. Jinxin Shuanghe leverages the extensive distribution and R&D network of its parent organization, China Resources Group, to maintain its market position.